Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price levels of Artemisininbased Combination Therapies (ACT). The CHAI's initiative is consistent with sanofi-aventis and DNDi' long-standing efforts to make ACTs more affordable and accessible to all malaria patients.

Sanofi-aventis and the non-profit Drugs for Neglected Diseases initiative (DNDi) welcome the agreement announced by Clinton Foundation HIV/AIDS Initiative (CHAI) to reduce the volatility and the price levels of Artemisininbased Combination Therapies (ACT). The CHAI's initiative is consistent with sanofi-aventis and DNDi' long-standing efforts to make ACTs more affordable and accessible to all malaria patients.

In late 2004 sanofi-aventis and DNDi announced a partnership to jointly develop a non-patented fixed-dose combination of artesunate and amodiaquine available to the public sector at a price of less than $1 for adults and less than $0.50 for children. This was achieved in 2007 with the launch of ASAQ Winthrop (ASAQ), which played a decisive role in encouraging all ACT manufacturers to aim for a similar price level.

Sanofi Aventis has one of the most ambitious pipelines in the industry for antimalarials and together with DNDi and other partners remain actively committed to the global fight against malaria. The Drugs for Neglected Diseases initiative (DNDi) is an independent, not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases such as malaria, leishmaniasis, human African trypanosomiasis, and Chagas disease.